Welcome to our dedicated page for Coeptis Therapeutics SEC filings (Ticker: COEP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Coeptis Therapeutics Holdings Inc. (Nasdaq: COEP) provides access to the company’s regulatory disclosures as it pursues both biopharmaceutical and technology-focused activities and a planned merger with Z Squared Inc. Company announcements reference a registration statement on Form S-4 filed with the U.S. Securities and Exchange Commission in connection with the proposed merger, and later note that this Form S-4 has been declared effective, allowing the company to mail a definitive proxy statement/prospectus for an Annual/Special Meeting of stockholders.
Through SEC filings such as the Form S-4, investors can review detailed information about the proposed business combination with Z Squared, including the structure of the merger, the intended spin-out of Coeptis’ biopharmaceutical operations, and the plan for the combined company to focus on digital asset mining while technology operations remain in the public entity. These filings also describe conditions to closing, such as regulatory approvals, shareholder approvals, and listing requirements.
For a company active in biotechnology and advanced technology, SEC reports can also provide context on licensed assets and business segments described in press releases, such as the allogeneic cellular immunotherapy platform and DVX201 NK cell therapy licensed from Deverra Therapeutics, the GEAR Cell Therapy Platform licensed from VyGen-Bio, and the SNAP-CAR technology licensed from the University of Pittsburgh. Filings may further explain how the Technology Division and the NexGenAI Affiliates Network fit into the overall business.
On Stock Titan, Coeptis-related SEC filings are supplemented with AI-powered summaries
Coeptis Therapeutics Holdings, Inc. files Supplement No. 2 to its S-4 prospectus to incorporate its Annual Report on Form 10-K for the year ended December 31, 2025. The 10-K discloses a net loss of $12,277,192 for 2025 and an accumulated deficit of $109,953,728. The filing states shares outstanding were 6,223,221 as of March 18, 2026 and reports an aggregate market value held by non-affiliates of $28,225,766 based on a $7.80 closing price.
The 10-K details biotech and technology divisions, material collaborations and licenses (including Deverra, Vy-Gen and the University of Pittsburgh), a going-concern explanatory paragraph, financing needs, and a pending merger/spin-out transaction expected to close in Q2 2026. Risk factors include substantial doubt about going concern, the cost and uncertainty of clinical development, reliance on partners, and the need for additional capital.
Coeptis Therapeutics Holdings, Inc. reported that Nasdaq has approved, subject to customary conditions and completion of the proposed merger with Z Squared Inc., the listing of the post-merger company’s common stock on the Nasdaq Global Market under the ticker symbol “ZSQR”.
The new listing is expected to take effect when the merger closes, at which point Z Squared will become a wholly owned subsidiary and Coeptis will change its corporate name to Z Squared Inc. Key closing conditions already satisfied include effectiveness of Coeptis’ registration statement on Form S-4 and shareholder approval of the merger proposals at the January 30, 2026 stockholders’ meeting.
The companies state that the business combination remains subject to remaining customary closing conditions and is expected to close in Q2 2026, though there is no assurance these conditions will be met.
The Vanguard Group filed an Amendment No. 1 to its Schedule 13G/A reporting for Coeptis Therapeutics Holdings Inc. The amendment states beneficial ownership of 0 shares (0%) of Common Stock as disclosed, and explains an internal realignment of Vanguard subsidiaries effective January 12, 2026.
Coeptis Therapeutics Holdings, Inc. registers an offering of 107,500 shares of common stock, pre-funded warrants to purchase 67,500 shares, Series A warrants to purchase 153,125 shares and Series B warrants to purchase 153,125 shares.
This prospectus supplement, dated March 23, 2026, supplements the June 14, 2023 prospectus and attaches the company’s Form 10-K for the year ended December 31, 2025. The supplement states none of the Series A or Series B warrants have been exercised and notes a 20-for-1 reverse stock split effected December 30, 2024. The Form 10-K discloses a going concern paragraph, net loss of $12,277,192 for 2025, accumulated deficit of $109,953,728, shares outstanding of 6,223,221 as of March 18, 2026, and market close price of $11.07 on March 19, 2026.
Coeptis Therapeutics Holdings, Inc. is registering the resale of up to 604,000 shares of its common stock on a resale basis to satisfy registration rights granted to certain selling stockholders, as set forth in a Prospectus Supplement dated March 23, 2026.
The 604,000 shares consist of issued shares and shares issuable upon exercise of various warrants and pre-funded warrants. Shares outstanding were 6,223,221 shares as of March 18, 2026. The company’s common stock traded at $11.07 on March 19, 2026 on the Nasdaq Capital Market under the symbol COEP.
Coeptis Therapeutics Holdings, Inc. registers the resale of up to 3,919,349 shares of Common Stock by selling stockholders via a prospectus supplement dated March 23, 2026. The amount includes 100,000 shares held by certain selling stockholders, up to 3,737,472 shares issuable to YA II PN, LTD. (“Yorkville”) under a Standby Equity Purchase Agreement, and 81,877 shares issued in partial conversion of a convertible note.
The supplement attaches the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and updates the base prospectus. Shares are being offered for resale by named selling stockholders rather than as a primary offering by the issuer. Shares outstanding were 6,223,221 as of March 18, 2026, and the Nasdaq closing price was $11.07 as of March 19, 2026.
Coeptis Therapeutics Holdings, Inc. files its annual report describing a small, development‑stage biopharmaceutical and technology company with no approved drugs, minimal revenue and a focus on cell therapies and AI‑driven marketing software. The biopharma division is advancing preclinical platforms including CD38‑GEAR‑NK, CD38‑Diagnostic, the SNAP‑CAR universal cell therapy platform and allogeneic NK programs licensed from Deverra.
In 2025 Coeptis recorded a net loss of $12,277,192, bringing its accumulated deficit to $109,953,728, and its auditors raise substantial doubt about its ability to continue as a going concern. The company reports only six employees and expects to continue incurring losses while it funds R&D and looks for partners.
Strategically, Coeptis acquired the NexGenAI Affiliates Network marketing automation platform and agreed in April 2025 to spin out its biotechnology assets to shareholders while merging with Z Squared, Inc., with closing expected in the second quarter of 2026. The company highlights significant regulatory, financing, competition and Nasdaq listing risks and operates as an emerging growth company using reduced reporting requirements.
Coeptis Therapeutics Holdings, Inc. Chief Financial Officer Brian Cogley increased his direct ownership of common stock through an option exercise and an equity grant. On February 11, 2026, he exercised stock options to acquire 10,000 shares of common stock at an exercise price of $10.56 per share, converting derivative securities into shares.
On the same date, he also received a grant of 12,500 shares of restricted stock in connection with an option exchange program, where previously granted underwater options were surrendered in exchange for restricted stock. Following these transactions, he directly beneficially owned 22,500 shares of common stock.
Coeptis Therapeutics Holdings, Inc. director Philippe Deschamps increased his direct common stock holdings through equity awards. On February 11, 2026, he acquired 5,700 shares of common stock by exercising stock options at $10.56 per share, classified as an exercise or conversion of a derivative security.
On the same date, he also received a grant of 3,250 shares of restricted stock at a stated price of $0. This restricted stock was issued in an option exchange program in which he surrendered underwater options in return for restricted shares. Following these transactions, he directly beneficially owned 8,950 shares of Coeptis common stock.